Form 8-K · Current Report · Filed 2024-04-08
Ionis Pharmaceuticals Announces Positive Phase 3 Results for Olezarsen in FCS
Ionis Pharmaceuticals, Inc. announced on April 7, 2024, the positive results from the Phase 3 Balance study of olezarsen, an investigational treatment for adults with familial chylomicronemia syndrome (FCS). The study met its primary endpoint, showing a statistically significant reduction in fasting triglycerides in patients treated with olezarsen 80 mg compared to placebo. Additionally, there was a substantial reduction in acute pancreatitis events and hospitalizations. The results were presented at the 2024 ACC Annual Meeting and published in The New England Journal of Medicine. Ionis is seeking regulatory approval for olezarsen as a potential breakthrough treatment for FCS.
- Filer
- Ionis Pharmaceuticals Inc. IONS · NASDAQ
- Filed
- Accession
- 0001140361-24-018449
- CIK
- 0000874015
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Other Events
Financial Statements and Exhibits
Market reaction
Close before filing
$43.22
Next session
-0.9%
Since filing
+19.8%
Latest close
$51.77
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from IONS reporting the same item, with the next session's move:
Exhibits (1)
About Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.
Never miss another IONS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.